An anxiolytic is a psychoactive substance whose principal effect — or principal sought effect — is the reduction of anxiety.[1] The class is defined by this functional endpoint rather than by a shared chemical scaffold or a single pharmacological target, which makes it inherently heterogeneous: membership is a question of clinical or self-reported intent.
The class spans several pharmacological families: GABAA positive allosteric modulators including the benzodiazepines diazepam, alprazolam, lorazepam, and clonazepam alongside designer analogues such as etizolam and clonazolam; the GABAB agonist phenibut; the calcium-channel α2δ ligands gabapentin and pregabalin; the 5-HT1A partial agonist buspirone; the plant preparation kava; and the amino acid theanine. These members differ widely in mechanism but converge on anxiety relief.
Anxiolytics are used across everyday, clinical, and self-managed contexts. In clinical practice they are prescribed for generalized anxiety, panic disorder, situational anxiety, and as adjuncts to surgical premedication. At low to moderate exposures the experiential signature is reduced worry and somatic tension; with the GABAergic members, deepening exposure shades into sedation, motor impairment, amnesia, and — at the upper end — respiratory suppression.[2]
Pharmacology
Because the anxiolytic class is organized around a functional outcome rather than a single receptor, members reach anxiolysis by chemically unrelated routes that converge on a shared physiological endpoint: reduced neuronal excitability in anxiety-mediating circuits, principally the amygdala, prefrontal cortex, and hippocampus.[2]
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| GABAA positive allosteric modulation | diazepam, alprazolam, clonazepam, etizolam, clonazolam | Potentiates GABA-mediated chloride conductance and hyperpolarizes neurons; α2- and α3-containing receptors carry the anxiolytic component, α1-containing receptors the sedative and amnesic component |
| GABAB agonism | phenibut, F-phenibut | Activates metabotropic GABAB receptors, increasing potassium conductance and reducing presynaptic calcium influx |
| Voltage-gated calcium channel α2δ binding | gabapentin, pregabalin | Binds the α2δ auxiliary subunit of presynaptic calcium channels, lowering glutamate release at over-active synapses; mechanism is not GABAergic |
| 5-HT1A partial agonism | buspirone | Acts as a near-full agonist at presynaptic raphe autoreceptors and a partial agonist at postsynaptic forebrain 5-HT1A receptors; effect emerges over days to weeks |
| Polymodal GABAA and channel modulation | kava | Kavalactones positively modulate GABAA at a site distinct from the benzodiazepine site (flumazenil-insensitive) and additionally block voltage-gated sodium and calcium channels[3] |
| Amino-acid modulation | theanine | Mild effects on GABA synthesis and glutamatergic signaling; clinical anxiolytic significance is debated |
What unites these mechanisms is the endpoint of net inhibition in anxiety circuits; what divides them is what else that inhibition produces. The GABAergic majority — benzodiazepines, their designer analogues, phenibut, and (through a distinct allosteric site) kava — additionally suppress brainstem arousal and respiratory drive, so the anxiolytic effect cannot be cleanly separated from a dose-dependent sedative-respiratory effect.[4]
The non-GABAergic members behave differently. Gabapentin and pregabalin reduce excitatory release without engaging GABA receptors at all,[5] and buspirone normalizes serotonergic tone without acute sedation or respiratory effect.[6] This split — GABAergic versus non-GABAergic mechanism — drives most of what follows on the page.
Substances
The class is illustrated by members from chemically and mechanistically unrelated families:
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Diazepam | Benzodiazepine | Long-acting reference benzodiazepine; the standard agent used in structured taper protocols |
| Alprazolam | Benzodiazepine | Short-acting, high-potency benzodiazepine widely prescribed for panic disorder |
| Lorazepam | Benzodiazepine | Intermediate-acting agent commonly used in acute clinical and inpatient settings |
| Clonazepam | Benzodiazepine | Long-acting agent used for both anxiety and seizure indications |
| Etizolam | Thienodiazepine | Designer analogue acting at the same allosteric site as benzodiazepines |
| Clonazolam | Designer benzodiazepine analogue | Notably high potency per milligram, narrowing the practical gap between an anxiolytic and an obtunding dose |
| Flubromazolam | Designer benzodiazepine analogue | High potency paired with a long half-life that complicates dose-titration outside controlled settings |
| Phenibut | GABAB agonist | β-phenyl-GABA; widely available outside pharmacies, with high dependence liability relative to its accessibility |
| Gabapentin | α2δ ligand | Non-GABAergic anxiolytic acting at presynaptic voltage-gated calcium channels |
| Pregabalin | α2δ ligand | Higher-affinity congener of gabapentin with established efficacy in generalized anxiety disorder[7] |
| Buspirone | 5-HT1A partial agonist | Non-sedating anxiolytic with no acute euphoria, no amnesia, and no meaningful dependence liability |
| Kava | Polymodal plant preparation | Traditional Pacific anxiolytic; kavalactones positively modulate GABAA at a non-benzodiazepine site |
| Theanine | Amino acid | Mild calmative present in green tea; no tolerance, dependence, or withdrawal documented at typical use levels |
These members produce anxiety reduction through completely different molecular routes. The GABAergic agents and the gabapentinoids dominate the clinical and harm-reduction literature, while buspirone and theanine sit in a mechanistically distinct corner where physical dependence is not a meaningful concern.
Subjective Effects
Because the class is mechanically split, the experiential trajectory differs between subgroups. For the GABAergic majority — benzodiazepines, their designer analogues, phenibut, and kava — exposure deepens along a single axis from anxiolysis into broader CNS inhibition. Buspirone's trajectory is gradual and lacks acute deepening; theanine sits at a mild calmative level without a meaningful dose ladder.[1]
| Exposure | Characteristic effects (GABAergic majority) |
|---|---|
| Low | Reduction of worry, somatic tension, and ruminative thinking; mild muscle relaxation; modest calm without prominent sedation |
| Moderate–high | Progressive sedation deepening toward hypnosis; anterograde amnesia (particularly with benzodiazepines); ataxia and impaired coordination; psychomotor slowing; increasing disinhibition |
| High | Stupor, loss of protective airway reflexes, and dose-dependent suppression of brainstem respiratory drive |
Within the GABAergic majority, the same axis that lowers anxiety also lowers arousal and breathing, and the margin between an effective anxiolytic dose and an obtunding one narrows as the depressant load rises — whether from designer-analogue potency, from a second GABAergic anxiolytic, or from concurrent alcohol or opioid use. Buspirone and theanine do not follow this hinge: neither produces acute sedation, amnesia, or respiratory suppression at typical use, and neither carries the dose-ladder pattern above.
Safety
Risk profile
The defining acute danger of the GABAergic majority of this class is additive CNS and respiratory depression in combination with other depressants — alcohol, opioids, or a second GABAergic anxiolytic. Two depressants together can produce the respiratory suppression ordinarily associated with high single-agent doses, and benzodiazepine involvement is a consistent finding in polydrug overdose surveillance.[2]
Combination risk extends across the GABAergic class. Benzodiazepine with alcohol, benzodiazepine with an opioid, benzodiazepine with phenibut, benzodiazepine with a gabapentinoid — all produce additive-to-synergistic depression, and the additivity is not limited to high-dose use. Several designer analogues — notably clonazolam, flualprazolam, and flubromazolam — are substantially more potent per milligram than pharmaceutical reference benzodiazepines, and some have very long half-lives; both features narrow the practical margin outside controlled settings.
Phenibut warrants a separate note. Acute high-dose intoxication can produce a sedative-dissociative state with severe respiratory depression and psychomotor collapse, and the dose-response curve shifts substantially with tolerance, so escalating doses become progressively more dangerous.[8]
Naloxone reverses opioid-mediated respiratory depression but does not reverse depression caused by benzodiazepines, phenibut, gabapentinoids, or alcohol — a critical point for emergency response when these are stacked. Flumazenil can reverse benzodiazepine effects but may precipitate seizures in dependent individuals and is not a routine pre-hospital intervention.
Buspirone and theanine sit outside this risk picture. Buspirone does not cause respiratory depression and does not potentiate opioid or alcohol toxicity through GABA-A mechanisms.[1] Theanine at typical use levels has no documented serious-adverse-outcome literature.
Tolerance & dependence
Tolerance and dependence are uneven across the class. Within the GABAergic majority, tolerance develops with regular use — most rapidly to sedative and anticonvulsant effects, more slowly and sometimes only partially to the anxiolytic effect itself.[4] Cross-tolerance is established within the GABA-A-modulating subgroup: tolerance to one benzodiazepine extends to other benzodiazepines, to alcohol, and to barbiturates. Physical dependence can develop within weeks of daily therapeutic use.
Phenibut withdrawal can include severe anxiety, psychosis with hallucinations, tremor, and autonomic instability, with cases requiring inpatient hospitalization.[10] People physically dependent on any of these agents should not stop abruptly; a supervised taper is the established approach.
Gabapentinoid dependence is milder than benzodiazepine dependence but clinically real. Abrupt cessation can produce anxiety, insomnia, sweating, and — less commonly — seizures, and tapering is standard. Kava is associated with a comparatively mild withdrawal syndrome — irritability, tremor, and rebound anxiety — without the seizure risk of the GABA-A-acting agents.
Buspirone produces no physical dependence and no clinically significant withdrawal syndrome on discontinuation. Importantly, it does not cross-tolerate with benzodiazepines: patients transitioning from long-term benzodiazepine therapy require a structured benzodiazepine taper first, because buspirone will not suppress benzodiazepine withdrawal.[1] Theanine has no documented tolerance, dependence, or withdrawal at typical use levels.
Recovery
Recovery from anxiolytic dependence is well-trodden clinical territory and the pathway is generally good. Medically supervised withdrawal management, gradual tapering — for benzodiazepines and their analogues a structured taper using a long-acting equivalent such as diazepam is standard, and for phenibut, baclofen has been used in case reports given the shared GABAB activity — and ongoing support substantially reduce the risks of cessation.If you or someone you know is dependent on a benzodiazepine, a designer analogue, phenibut, or a gabapentinoid, a clinician or a withdrawal-management service can structure a safe taper. For the non-GABAergic members, dependence is not a meaningful concern, and any psychological aspects of long-term use can be addressed in ordinary therapeutic settings.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1]
- [2] ^abcEngin E (2022) GABA-A receptor subtypes and benzodiazepine use, misuse, and abuse — Frontiers in Psychiatry doi:10.3389/fpsyt.2022.1060949
- [3] ^Chua HC, Christensen ET, Hoestgaard-Jensen K, et al. (2016) Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism — PloS One doi:10.1371/journal.pone.0157700
- [4] ^abVinkers, C.H. and Olivier, B. (2012) Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? — Advances in Pharmacological Sciences doi:10.1155/2012/416864
- [5] ^Taylor, C.P. (2009) Mechanisms of analgesia by gabapentin and pregabalin -- calcium channel alpha2-delta [Cavalpha2-delta] ligands — Pain doi:10.1016/j.pain.2008.11.019
- [6] ^Loane, C. and Politis, M. (2012) Buspirone: what is it all about? — Brain Research doi:10.1016/j.brainres.2012.04.032